Credit Suisse’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Credit Suisse’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-350	Closed	-$9.42K	–	3293
2023 Q1	$9.42K	Hold	350	–	–	﹤0.01%	3256
2022 Q4	$12.4K	Sell	350 -8	-2%	-$961	﹤0.01%	3499
2022 Q3	$81K	Buy	358 +6	+2%	+$1.48K	﹤0.01%	3477
2022 Q2	$66K	Buy	+352	New	+$71K	﹤0.01%	3598
2021 Q1	–	Sell	-4,616	Closed	-$1.7M	–	4635
2020 Q4	$1.7M	Buy	4,616 +318	+7%	+$91.2K	﹤0.01%	2943
2020 Q3	$1.05M	Sell	4,298 -62	-1%	-$19.3K	﹤0.01%	2892
2020 Q2	$1.26M	Buy	4,360 +593	+16%	+$175K	﹤0.01%	2746
2020 Q1	$768K	Buy	3,767 +615	+20%	+$196K	﹤0.01%	2862
2019 Q4	$1.41M	Sell	3,152 -1,368	-30%	-$486K	﹤0.01%	2892
2019 Q3	$1.39M	Buy	+4,520	New	+$1.47M	﹤0.01%	2759
2015 Q3	–	Sell	-55	Closed	-$31K	–	4534
2015 Q2	$31K	Sell	55 -186	-77%	-$515K	﹤0.01%	4489
2015 Q1	$2.06M	Buy	241 +64	+36%	+$559K	﹤0.01%	2375
2014 Q4	$1.56M	Buy	177 +94	+113%	+$546K	﹤0.01%	2758
2014 Q3	$389K	Buy	83 +58	+232%	+$306K	﹤0.01%	3795
2014 Q2	$180K	Buy	+25	New	+$125K	﹤0.01%	4406

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Credit Suisse's EIGR Position: Q2 2023 in Review

Credit Suisse sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 350 shares — an estimated $9.42K sold.

Credit Suisse first reported a position in EIGR in Q2 2014 and held it in 15 quarters. The position peaked at $2.06M in Q1 2015. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

Credit Suisse reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Credit Suisse sold 350 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $9.42K.
Credit Suisse first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 15 quarters.
Credit Suisse's Eiger BioPharmaceuticals, Inc. position peaked at $2.06M in Q1 2015.
66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.